Reardon Andrew sold $91K of LGND
Reardon Andrew (CLO & Secretary) sold 400 shares of LIGAND PHARMACEUTICALS INC (LGND) at $226.78 on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The event updates the insider ownership record but does not provide new company fundamentals (no guidance, trial, regulatory, or deal information).
Market read
Traders may treat this as a minor sentiment datapoint; it is unlikely to drive a directional trade absent other catalysts.
What to watch
The disclosure doesn’t reveal reasons for the sale, tax planning, diversification, or option/RSU mechanics; without additional filings, signal quality is limited.
Background
This is a SEC Form 4 insider transaction: an officer (CLO & Secretary) reported an open-market sale executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Ligand Pharmaceuticals insider Andrew Reardon sold 400 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other company-specific news.
Form 4 sales under a 10b5-1 plan are typically scheduled and often not interpreted as a directional signal, especially with a small dollar value.
Market effects
Minimal—single-company insider sale without accompanying operational/clinical/regulatory updates.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with perceived near-term risk; traders may watch for follow-on sales or larger transactions.
Key entities
- issuerLigand Pharmaceuticals Inc
Subject of the Form 4 insider sale disclosure (LGND).
- insiderAndrew Reardon
CLO & Secretary who sold 400 shares under a 10b5-1 plan.
